Huntingtons disease (HD) is an autosomal dominant progressive neurodegenerative disorder, clinically characterized by cognitive impairment, chorea and dystonia, bradykinesia, uncoordinated movement, mood disorder and other psychiatric symptoms, and behavioral difficulties (Huntington Study Group, 1996)
The outcomes described in this publication represent possibilities rather than guarantees, and some individuals may experience minimal noticeable benefits despite appropriate use
GHK-Cu cannot
BPC-157/TB-500/GHK-Cu 10+10+50mg (GLOW blend 70mg) $200.00 Volume discounts Auto-applied at checkout Free shipping on orders of $200+ Compound Identity COMPOUND NAME BPC+TB500+GHK-Cu SYNONYMS GLOW blend CAS NUMBER 137525-51-0 (BPC-157), 77591-33-4 (TB500), 300801-03-0 (GHK-Cu) MOLECULAR FORMULA C 62 H 98 N 16 O 22 (BPC-157), C 212 H 350 N 56 O 78 S (TB500), C 28 H 46 CuN 12 O 8 (GHK-Cu) MOLECULAR WEIGHT ~6786.95 g/mol STRUCTURE Multi-peptide blend PEPTIDE SEQUENCE Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (BPC-157), Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (TB500), Gly-His-Lys (GHK-Cu) CHEMICAL STRUCTURE Molecular Formula : C 62 H 98 N 16 O 22 (BPC-157), C 212 H 350 N 56 O 78 S (TB500), C 28 H 46 CuN 12 O 8 (GHK-Cu) Source: PubChem Mechanism of Action GLOW blend works through multiple complementary biological pathways that promote tissue repair, regeneration, and inflammation control
Translating research into policy and action
In abdominal aortic aneurysm (AAA), SENP3 increases macrophage ferroptosis and aggravates inflammation
